Literature DB >> 8401125

Measuring the impact of menopausal symptoms on quality of life.

E Daly1, A Gray, D Barlow, K McPherson, M Roche, M Vessey.   

Abstract

OBJECTIVE: To examine the impact of menopausal symptoms on the overall quality of life of women.
DESIGN: Data collection with a questionnaire administered by an interviewer, incorporating two different quality of life measurement techniques (time trade off and rating scale).
SETTING: Specialist menopause clinic and two general practices in Oxford.
SUBJECTS: 63 women aged 45-60 years recruited opportunistically during a clinic or appointment with a general practitioner; no exclusion criteria.
RESULTS: Subjects gave very low quality of life ratings for health states with menopausal symptoms. The time trade off method of measuring preferences for these health states (on a scale from 0 to 1, where preference for full health is given as 1) yielded utility values of 0.64 for severe menopausal symptoms and 0.85 for mild symptoms. The rating scale measurement technique yielded even lower values: utilities of 0.30 and 0.65 were obtained for severe and mild symptoms respectively. Kappa scores indicated that the two methods produced results that were poorly related but not contradictory. Comparison of quality of life ratings before and after treatment with hormone replacement therapy showed significant improvements: with the rating scale measurement technique mean increases in utility values after the relief of severe and mild menopausal symptoms were 0.56 and 0.18 respectively.
CONCLUSIONS: Quality of life may be severely compromised in women with menopausal symptoms, and perceived improvements in quality of life in users of hormone replacement therapy seem to be substantial. This emphasises the need to include quality of life measurements when assessing outcomes of hormone replacement therapy. Several limitations may exist with widely applied measurement techniques, calling for the development of appropriate and well validated instruments for measuring quality of life associated with reduced health states.

Entities:  

Mesh:

Year:  1993        PMID: 8401125      PMCID: PMC1678884          DOI: 10.1136/bmj.307.6908.836

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  25 in total

1.  HRT: an analysis of benefits, risks and costs.

Authors:  E Daly; M Roche; D Barlow; A Gray; K McPherson; M Vessey
Journal:  Br Med Bull       Date:  1992-04       Impact factor: 4.291

2.  Quality of life measures in health care. I: Applications and issues in assessment.

Authors:  R Fitzpatrick; A Fletcher; S Gore; D Jones; D Spiegelhalter; D Cox
Journal:  BMJ       Date:  1992-10-31

3.  Compliance with hormonal replacement therapy.

Authors:  B G Wren; L Brown
Journal:  Maturitas       Date:  1991-03       Impact factor: 4.342

4.  Quality of life measures in health care. III: Resource allocation.

Authors:  D J Spiegelhalter; S M Gore; R Fitzpatrick; A E Fletcher; D R Jones; D R Cox
Journal:  BMJ       Date:  1992-11-14

5.  Evaluation of an estrogen, androgen, estrogen-androgen combination, and a placebo in the treatment of the menopause.

Authors:  R B GREENBLATT; W E BARFIELD; J F GARNER; G L CALK; J P HARROD
Journal:  J Clin Endocrinol Metab       Date:  1950-12       Impact factor: 5.958

6.  The menopausal syndrome.

Authors:  S M McKinlay; M Jefferys
Journal:  Br J Prev Soc Med       Date:  1974-05

7.  Effects of "natural oestrogen" replacement therapy on menopausal symptoms and blood clotting.

Authors:  J Coope; J M Thomson; L Poller
Journal:  Br Med J       Date:  1975-10-18

8.  Oestrogen therapy and the menopausal syndrome.

Authors:  S Campbell; M Whitehead
Journal:  Clin Obstet Gynaecol       Date:  1977-04

9.  Effect of oestrogen on the sleep, mood, and anxiety of menopausal women.

Authors:  J Thomson; I Oswald
Journal:  Br Med J       Date:  1977-11-19

10.  A longitudinal analysis of women's attitudes toward the menopause: results from the Massachusetts Women's Health Study.

Authors:  N E Avis; S M McKinlay
Journal:  Maturitas       Date:  1991-03       Impact factor: 4.342

View more
  53 in total

Review 1.  Effect of SERMs on the uterus and menopausal symptoms.

Authors:  M Dören
Journal:  J Endocrinol Invest       Date:  1999-09       Impact factor: 4.256

2.  The ethics of aggregation and hormone replacement therapy.

Authors:  A D Lyerly; E R Myers; R R Faden
Journal:  Health Care Anal       Date:  2001

Review 3.  Valuing health-related quality of life. Issues and controversies.

Authors:  P Dolan
Journal:  Pharmacoeconomics       Date:  1999-02       Impact factor: 4.981

4.  Hysterectomy status, estrogen use and quality of life in older women: the Rancho Bernardo study.

Authors:  Donna Kritz-Silverstein; Denise G Von Muhlen; Theodore G Ganiats; Elizabeth Barrett-Connor
Journal:  Qual Life Res       Date:  2004-02       Impact factor: 4.147

5.  Women's quality of life in the premenopausal and postmenopausal periods.

Authors:  Sevgi Ozkan; Erkan S Alataş; Mehmet Zencir
Journal:  Qual Life Res       Date:  2005-10       Impact factor: 4.147

6.  Hormone replacement therapy: knowledge, attitudes, and well-being among middle-aged Australian women.

Authors:  K France; C Lee; M Schofield
Journal:  Int J Behav Med       Date:  1996

7.  Nonhormonal management of hot flashes for women on risk reduction therapy.

Authors:  Kostandinos Sideras; Charles L Loprinzi
Journal:  J Natl Compr Canc Netw       Date:  2010-10       Impact factor: 11.908

Review 8.  Viscosupplementation for osteoarthritis: a primer for primary care physicians.

Authors:  M Carrington Reid
Journal:  Adv Ther       Date:  2013-11-08       Impact factor: 3.845

9.  Women's use of hormone replacement therapy for relief of menopausal symptoms, for prevention of osteoporosis, and after hysterectomy.

Authors:  F Griffiths; B Convery
Journal:  Br J Gen Pract       Date:  1995-07       Impact factor: 5.386

10.  Temporal associations of hot flashes and depression in the transition to menopause.

Authors:  Ellen W Freeman; Mary D Sammel; Hui Lin
Journal:  Menopause       Date:  2009 Jul-Aug       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.